Dr. Sabari on Immunotherapy Updates in Small Cell Lung Cancer

Joshua Sabari, MD
Published: Friday, Oct 14, 2016



Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses recent findings in immunotherapy as potential treatment for patients with small cell lung cancer (SCLC). Sabari shared these insights during an interview at the 2016 IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

Recent clinical trial findings demonstrated strong antitumor activity with the PD-1 inhibitor nivolumab (Opdivo), as well as combination therapy with nivolumab and the CTLA-4 inhibitor ipilimumab (Yervoy). Further studies are ongoing to shed light on the activity of this and other combinations, Sabari explains.

This leads to a promising era in the field of SCLC, as there, historically, have been less effective treatment options. FDA approvals of such treatments could improve quality of life for patients.


Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses recent findings in immunotherapy as potential treatment for patients with small cell lung cancer (SCLC). Sabari shared these insights during an interview at the 2016 IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

Recent clinical trial findings demonstrated strong antitumor activity with the PD-1 inhibitor nivolumab (Opdivo), as well as combination therapy with nivolumab and the CTLA-4 inhibitor ipilimumab (Yervoy). Further studies are ongoing to shed light on the activity of this and other combinations, Sabari explains.

This leads to a promising era in the field of SCLC, as there, historically, have been less effective treatment options. FDA approvals of such treatments could improve quality of life for patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x